

**23 February 2023**

**Oncimmune Holdings plc**  
("Oncimmune" or the "Company")

**Appointment of Joint Broker**

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces the appointment of Zeus Capital Limited as a joint broker to the Company.

**For further information:**

**Oncimmune Holdings plc**

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[contact@oncimmune.co.uk](mailto:contact@oncimmune.co.uk)

**Singer Capital Markets (Nominated Adviser and Joint Broker)**

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

**Zeus (Joint Broker)**

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

**About Oncimmune**

***ImmunoINSIGHTS Service Business***

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immunoncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

***EarlyCDT Product Business***

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit [www.oncimmune.com](http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPDDGDDGXDDGXD